Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

Clinical trial NCT02674750 · COMPLETED

Trial details

NCT number: NCT02674750
Sponsor: Curis, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Start date: 2016-07-01
Primary completion: 2019-05-28
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.